NASDAQ:ATAI Atai Beckley Q4 2025 Earnings Results & Report Atai Beckley beat analyst earnings expectations but missed on revenue in its Q4 2025 results, released March 7, 2026. The company reported EPS of -$0.05 versus the -$0.12 consensus estimate, while revenue of $1.07 million fell short of the $1.50 million estimate by $434.00 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 7, 2026TimeBefore Market Opens Atai Beckley EPS ResultsActual EPS-$0.05Consensus EPS -$0.12Beat/MissBeat by +$0.07One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersAtai Beckley Revenue ResultsActual Revenue$1.07 millionExpected Revenue$1.50 millionBeat/MissMissed by -$434.00 thousandYoY Revenue GrowthN/AUpcoming EarningsAtai Beckley's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Atai Beckley Q4 2025 Earnings FAQ Did Atai Beckley beat earnings estimates for Q4 2025? Atai Beckley (NASDAQ:ATAI) reported earnings of -$0.05 per share for Q4 2025, beating the consensus estimate of -$0.12. The report was announced on Saturday, March 7, 2026. What was Atai Beckley's revenue for Q4 2025? Atai Beckley reported revenue of $1.07 million for Q4 2025, against a consensus estimate of $1.50 million. When is Atai Beckley's next earnings date? Atai Beckley's next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Atai Beckley on the company's earnings history page. Atai Beckley Earnings HeadlinesAtaiBeckley (ATAI) Stock Could Be Overvalued Given Its Rich Book ValueNovember 1, 2026 | finance.yahoo.comAtaiBeckley (ATAI) Stock May Be Fully Priced Given Its Balance SheetOctober 19, 2026 | uk.finance.yahoo.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.November 11 at 1:00 AM | Weiss Ratings (Ad)Eli Lilly Completes Acquisition of AtaiBeckleySeptember 11, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Genmab (GMAB), Definitive Healthcare Corp (DH) and Atai Beckley N.V. (ATAI)August 13, 2026 | theglobeandmail.comAtaiBeckley Inc.August 5, 2026 | cnn.comSee More Atai Beckley Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Atai Beckley? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atai Beckley and other key companies, straight to your email. Email Address About Atai BeckleyAtaiBeckley AG (NASDAQ: ATAI) is a clinical-stage biopharmaceutical company developing psychedelic and other novel therapeutics for mental health conditions. The company was formed through the combination of atai Life Sciences and Beckley Psytech and focuses on treatments intended to address conditions such as depression, anxiety, post-traumatic stress disorder and substance-use disorders. Its development programs include VLS-01, an investigational formulation of N,N-dimethyltryptamine (DMT), and BPL-003, an intranasal formulation of 5-MeO-DMT being studied for conditions including alcohol use disorder and depression. AtaiBeckley also evaluates non-psychedelic compounds and digital or technology-enabled treatment approaches intended to support the development and delivery of mental health therapies. Its products remain investigational and are not broadly approved for commercial use. The company operates internationally, with activities and research programs spanning the United States and Europe. AtaiBeckley is led by co-founder and Chief Executive Officer Florian Brand. Beckley Psytech was founded by Amanda Feilding, whose work in psychedelic research and drug development contributed to the company’s combined platform. View Atai Beckley ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Kinder Morgan's Chairman Just Bought $15 Million in StockA $4 Billion Jolt: NRG Energy Powers Data Center AmbitionsD-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?Archer Aviation's FAA Certificate Is a Milestone, But It Isn't the Final OneRocket Lab's Record Backlog Could Fuel a Rebound, But Neutron Raises the StakesDraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger Opportunity Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
